ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 0662 • ACR Convergence 2023

    Changes in Treatment Patterns and Their Influence on the Outcome of Systemic Sclerosis-interstitial Lung Disease (SSc-ILD) Patients: An EUSTAR Analysis

    Corrado Campochiaro1, Marie-Elise Truchetet2, Madelon Vonk3, Giovanna Cuomo4, Lidia P Ananieva5, Eric Hachulla6, Vanessa Smith7, Ana Maria Gheorghiu8, Radim Becvar9, Nicolas Hunzelmann10, Daniel Furst11, Vera Ortiz-Santamaria12, Patricia Carreira13, Francesco Del Galdo14, marco Matucci Cerinic15 and Anna Maria Hoffmann-Vold16, 1IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, 2Bordeaux University Hospital, Bordeaux, France, 3Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, Naples, Italy, 5V.A. Nasonova Research Institute Of Rheumatology Russian Federation, Moscow, Russia, 6University of Lille, Lille, France, 7Ghent University Hospital, Gent, Belgium, 8Department of Internal Medicine and Rheumatology, Ion Cantacuzino Clinical Hospital, Bucharest, Romania, 9Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic, 10University of Kšln, Kšln, Germany, 11University of California Los Angeles, Los Angeles, CA, 12University of Granollers, Granollers, Spain, 13Hospital Universitario 12 de Octubre, Madrid, Spain, 14University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, 15Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, 16Oslo University Hospital, Department of Rheumatology, Oslo, Norway

    Background/Purpose: The treatment armamentarium with immunosuppressive treatments (ISTs) for interstitial lung disease (ILD) in systemic sclerosis (SSc) has greatly expanded. It is to date unclear…
  • Abstract Number: 1050 • ACR Convergence 2023

    Diagnostic Accuracy of Lung Ultrasound for Detecting Interstitial Lung Disease Among Patients with Systemic Sclerosis: A Comparative Study of Two Scanning Protocols

    Fabian Carranza Enriquez1, Carina Soto-Fajardo1, Sinthia Solorzano Flores1, Abish Angeles-Acuña1, Mayra Mejia-Avila2, Amyrari Vázquez-Ortega3, Paola Flores-Ordoñez2, Karina Arias Callejas2, Alejandra Enriquez-Luna4, Graciliano Ramon-Diaz4, Brenda Bravo-Zarate2, Tatiana Sofía Rodríguez-Reyna3 and Carlos Pineda4, 1Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, 2Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, 3Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Instituto Nacional de Rehabilitacion, Mexico City, Mexico

    Background/Purpose: Lung ultrasound (LUS) has proven useful to detect interstitial lung disease (ILD) among patients with SSc when compared to high-resolution computerized tomography (HRCT) as…
  • Abstract Number: 1374 • ACR Convergence 2023

    Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival

    Marco Sprecher1, Florine Weber2, Kastriot Kastrati3, Helmut Prosch4, Natasha Moe5, Emily Langballe6, Cosimo Bruni7, Oyvind Molberg8, Phuong Phuong Diep9, Christian Clarenbach10, Paul Studenic11, Helena Andersson8, Oyvind Midtvedt12, Torhild Garen8, Karoline Lerang13, Thomas Frauenfelder14, Helga Radner15, Oliver Distler7 and Anna Maria Hoffmann-Vold16, 1Dept of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 2Dept of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 3Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, 4Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, 5Dept of Radiology, University Hospital Oslo, Oslo, Norway, 6Universitetet i Oslo, Oslo, Norway, 7Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, 9Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, 10Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 11Medical University of Vienna and Karolinska Institutet (sweden), Vienna, Austria, 12Oslo University Hospital, Oslo, Norway, 13Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 14Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 15Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 16Oslo University Hospital, Department of Rheumatology, Oslo, Norway

    Background/Purpose: Interstitial lung disease (ILD) has been reported to be present in 10-15% of patients with primary Sjögren's syndrome (pSS). Knowledge on risk factors predicting…
  • Abstract Number: 1774 • ACR Convergence 2023

    Gut Microbiota and Permeability Biomarkers for Diagnosis and Prognosis in Rheumatoid Arthritis Associated Interstitial Lung Disease

    José Lisbona-Montañez1, Patricia Ruiz-Limon2, Arkaitz Mucientes3, Natalia Mena Vazquez4, Isabel Moreno-Indias3, SARA MANRIQUE5, Laura Cano-García6, Rocío Redondo-Rodríguez6, Francisco J tinahones3 and Antonio Fernandez-Nebro7, 1Universidad de Málaga, Departamento de Medicina y Dermatología, Moclinejo, Spain, 2IBIMA Plataforma BIONAND, Cordoba, Spain, 3IBIMA Plataforma BIONAND, Málaga, Spain, 4IBIMA, Málaga, Spain, 5Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, 6Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, 7Hospital Regional Universitario de Málaga, Malaga, Spain

    Background/Purpose: Gut microbiota has been related to rheumatoid arthritis (RA), inflammation, and it's severity. Interstitial lung disease (ILD) is the most frequent non-pleural pulmonary manifestation…
  • Abstract Number: 2188 • ACR Convergence 2023

    Lung Cysts in Primary SS: New Findings on an Allegedly Innocuous Iiagnosis

    Regis Sewa Marques, Maria Fernanda Zacarin, Pamela Bellini, Raissa Dudienas D Pereira, Aloma Guinami Scabora, Zoraida Sachetto, Manoel Bertolo and ALISSON PUGLIESI, Universidade Estadual de Campinas, Campinas, Brazil

    Background/Purpose: Lung cysts are a frequent finding in patients with SS, with previous data indicating a prevalence of approximately 30% on chest CT scans. In…
  • Abstract Number: 0393 • ACR Convergence 2023

    Pulmonary Involvement in Patients with Seropositive and ACPA Positive Rheumatoid Arthritis (RA-ILD) – Novel Screening Protocol for Early Detection of Pulmonary Involvement

    Florian Popp1, Martin Hoffmann2, Johannes von Kempis3, Martin Welcker1, Werner von Wulffen2 and Frank Reichenberger2, 1Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, 2Augustinum Klinik München, Department of pneumology, Munich, Germany, 3Kantonsspital St. Gallen, Division of rheumatology and immunology, St. Gallen, Switzerland

    Background/Purpose: Seropositive and ACPA positive Rheumatoid Arthritis (RA) is associated with significant cardiovascular and pulmonary comorbidity. However, screening for early detection of pulmonary involvement especially…
  • Abstract Number: 0748 • ACR Convergence 2023

    Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT

    Kastriot Kastrati1, Thomas S Nakuz2, Oana C Kulterer2, Stephan Blüml3, Michael Bonelli3, Irina Gessl4, Hans-Peter Kiener3, Werner Langsteger2, Daniel Mrak3, Florian Prayer5, Helmut Prosch5, Elisabeth Simader3, Tatjana Traub-Weidinger2, Daniel Aletaha6, Helga Radner7, Marcus Hacker2 and Peter Mandl3, 1Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, 2Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 4Department of Rheumatology, Medical University of Vienna, Vienna, Austria, 5Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, 6Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, 7Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of idiopathic inflammatory myopathies (IIM) ranging up to 78% in IIM and is a key contributor…
  • Abstract Number: 1137 • ACR Convergence 2023

    Association Between Nailfold Videocapillaroscopy Findings and sKL-6 Levels in Patients with Idiopathic Inflammatory Myopathies–Related Interstitial Lung Disease

    Cristiana Sieiro Santos1, Jose Luis Tandaipan2, Diego Castillo2, Laura Martínez Martínez2, Helena Codes2, Luis Sainz-Comas2, Berta Paula Magallares-Lopez3, Patricia Moya2, Anais Mariscal2, Hye Sang Park2, Ana Milena Millán Arciniegas2, César Díaz-Torné2, Ana Laíz Alonso2, Sandra Ros2, Susana Fernández2, Hector Corominas4, Elvira Díez Álvarez5 and Iván Castellvi2, 1Complejo Asistencial Universitario de León, León, Spain, 2Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 3Department of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, 4Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, 5CAULE, León, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a frequent pulmonary manifestation in idiopathic inflammatory myopathies (IIM) (IIM-ILD) and considerably influences morbidity and mortality. Krebs von den…
  • Abstract Number: 1377 • ACR Convergence 2023

    Characterization of Pulmonary Manifestations of Sjögren Syndrome: A Multicenter Retrospective Study

    Loïc Meudec1, Cindy Marques2, Pierre-Antoine Juge3, Robin Dhote4, Anne-Laure Fauchais5, Emanuelle Dernis6, Olivier Vittecoq7, Alain SARAUX8, Jacques-Eric Gottenberg9, Eric Hachulla10, Véronique Le Guern11, Philippe Dieudé12, Marie-Pierre Debray13, Antoine Beurnier14, Raphaele Seror15, Xavier Mariette16 and Gaetane Nocturne17, 1CHU Kremlin-Bicêtre, Rheumatology, Le Kremlin-Bicêtre, France, 2CHU Pitié Salpétrière, Internal Medicine 1, Paris, France, 3Division of Rheumatology, Inflammation, and Immunity Brigham & Women’s Hospital, Boston, MA, 4Department of Internal Medicine, Centre Hospitalier Avicenne, Bobigny, France, 5Dupuytren Hospital, Limoges, France, 6CH Le Mans, Le Mans, France, 7CHU Rouen, Rheumatology, Rouen, France, 8CHU Brest, Brest, France, 9Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, 10CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, 11APHP Hôpital Cochin, Paris, France, 12Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France, 13CHU Bichat, Radiology, Paris, France, 14CHU Kremlin-Bicêtre, Functional Explorations, Le Kremlin-Bicêtre, France, 15University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, 16Université Paris-Saclay, Le Kremlin-Bicêtre, France, 17APHP, Le Kremlin-Bicêtre, France

    Background/Purpose: Sjögren disease (Sjo) is a systemic immune-related disease with pulmonary manifestations occurring in up to 16% of patients [1], including interstitial lung disease (SS-ILD)…
  • Abstract Number: 1884 • ACR Convergence 2023

    Which Cell Pattern in Immunological Bronchoalveolar Lavage (BAL) Is Associated with a High-resolution Computer Tomography (HRCT) Pattern at the Onset of Inflammatory Rheumatic Disease with Interstitial Lung Disease?

    tobias Hoffmann1, Martin Förster2, Peter Oelzner1, Claus Kroegel2, Ulf Teichgräber3, Diane Renz4, Joachim Böttcher1, Christian Schulze2, Gunter Wolf1, Marcus Franz2 and Alexander Pfeil1, 1Department of Internal Medicine III, Jena University Hospital – Friedrich Schiller University Jena, Jena, Germany, 2Department of Internal Medicine I, Jena University Hospital – Friedrich Schiller University Jena, Jena, Germany, 3Institute of Diagnostic and Interventional Radiology, Jena University Hospital – Friedrich Schiller University Jena, Jena, Germany, 4Institute of Diagnostic and Interventional Radiology, Department of Pediatric Radiology, Hannover Medical School, Hannover, Germany

    Background/Purpose: Inflammatory rheumatic diseases (IRD) are associated with interstitial lung disease (ILD). High-resolution Computer Tomography (HRCT) is recommended as goldstandard in the detection of IRD-ILD.…
  • Abstract Number: 2352 • ACR Convergence 2023

    High Serum C-X-C Motif Chemokine Ligand 10 (CXCL10) Potentially Predicts New Onset of Systemic Sclerosis-Interstitial Lung Disease

    Yehya Al-Adwi, Isabella Atzeni, Berber Doornbos-van der Meer, Marcel J van der Leij, Bart-Jan Kroesen, Alja Stel, Wim Timens, C.Tji Gan, Harry van Goor, Johanna Westra and Douwe J Mulder, University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of death in SSc patients. There is an unmet need for predictive biomarkers of ILD…
  • Abstract Number: 0420 • ACR Convergence 2023

    Associations and Mortality Impact of Machine Learning-derived Quantitative Computed Tomography Parenchymal Lung Features in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort of Smokers

    Gregory McDermott1, Keigo Hayashi1, Matthew Moll1, Michael Cho1, Kazuki Yoshida1, Tracy J. Doyle1, Gregory Kinney2, Paul Dellaripa3, Zachary Wallace4, Elizabeth Regan5, Gary Hunninghake1, Edwin Silverman1, Samuel Ash1, Raul San Jose Estepar1, George Washko1 and Jeffrey Sparks6, 1Brigham and Women's Hospital, Boston, MA, 2University of Colorado Denver, Denver, CO, 3Brigham and Women's Hospital, Boston, MA, 4Massachusetts General Hospital, Newton, MA, 5National Jewish Health, Denver, CO, 6Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Quantitative computed tomography (QCT) methods have been developed to automatically quantify parenchymal lung features on chest CT imaging. There have been limited investigations of…
  • Abstract Number: 0769 • ACR Convergence 2023

    Development and Validation of a Combined Clinical and Genetic Risk Score for Interstitial Lung Disease in a Large, Multicenter, Prospective Rheumatoid Arthritis Cohort

    Austin Wheeler1, Joshua Baker2, Yangyuna Yang1, Punyasha Roul1, K Wysham3, Grant Cannon4, Gary Kunkel5, Gail Kerr6, Dana Ascherman7, Paul Monach8, Andreas Reimold9, Jill Poole1, Tony Merriman10, Ted R Mikuls11 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3VA Puget Sound/University of Washington, Seattle, WA, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5University of Utah, Salt Lake City, UT, 6Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 7University of Pittsburgh, Pittsburgh, PA, 8VA Boston Healthcare System, Boston, MA, 9University of Texas Southwestern Medical Center, Dallas, TX, 10University of Alabama at Birmingham, Birmingham, AL, 11Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA that causes substantial morbidity and mortality. Although some clinical and genetic risk…
  • Abstract Number: 1142 • ACR Convergence 2023

    A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease

    Nikita Jhawar, Claire Wilson, Andy Abril, Li Zhuo and Yaohua Ma, Mayo Clinic, Jacksonville, FL

    Background/Purpose: Connective tissue diseases such as scleroderma are frequently associated with interstitial lung disease (ILD). Detection of autoantibodies is crucial in characterizing disease phenotypes, but…
  • Abstract Number: 1378 • ACR Convergence 2023

    The UCSD Shortness of Breath Questionnaire Is a Useful Tool for the Assessment of Dyspnea in Primary Sjögren’s Syndrome Patients with Interstitial Lung Disease: A Monocentric Cross-Sectional Study

    Gaetano La Rocca1, Francesco Ferro2, Elena Elefante3, Silvia Fonzetti4, Giovanni Fulvio5, Inmaculada Conception Navarro Garcia3, Chiara Romei6, Marta Mosca3 and Chiara Baldini5, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, 3Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, 4AOUP, Pisa, Italy, 5University of Pisa, Pisa, Italy, 6Department of Diagnostic Imaging, Diagnostic Radiology 2, Pisa University Hospital, Pisa, Italy

    Background/Purpose: In clinical trials investigating new drugs for the management of Interstitial Lung Disease (ILD) patient reported outcomes (PRO) are increasingly employed as outcome measures…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 39
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology